FMT restores gut microbiota balance in GC patients by promoting SCFA-producing bacteria, which modulate the immune system. Butyrate downregulates the NLRP3 inflammatory pathway, inhibits macrophage activation, and reduces intestinal inflammation, improving nutrient absorption. Here, NLRP3 is linked to gastric cancer.